Overview

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

Status:
Not yet recruiting

Trial end date:
2022-03-05

Target enrollment:

Participant gender:

Summary

This study will investigate changes in insulin sensitivity, lipid metabolism and endocrine profile in HIV-negative subjects exposed to Biktarvy (B/F/TAF) compared to subject not exposed to B/F/TAF for 28 days.

Phase:

Phase 1

Details

Lead Sponsor:

Chelsea and Westminster NHS Foundation Trust

Treatments:

Emtricitabine